UCLA Campus    |   UCLA Health    |   School of Medicine Translate:
UCLA Health It Begins With U

HIFU Treatment for Recurrent Prostate Cancer

Print
Email
What Is UCLA Health?

UCLA Clinical Trial Offers Additional Option for Patients with Recurrent Prostate Cancer

This video is also available in Windows Media at
http://streaming.uclahealth.org/hifu

Dwight Baird - UCLA HIFU Patient 

Dwight Baird
UCLA High Intensity Focused Ultrasound (HIFU) Patient

 
Dr. Leonard Marks
Leonard Marks, MD
Professor, UCLA Department of Urology
 
Dr. Allan Pantuck 
Allan J. Pantuck, MD
Associate Professor, UCLA Department of Urology

Dwight's Story

Dwight Baird's prostate cancer had returned after he initially received external beam radiation treatment 22 years ago.  He wasn't a candidate for further radiation or surgery to remove the prostate so his options were limited. 

Dwight chose a new non-invasive treatment currently only being offered through clinical trials at academic sites in the United States - UCLA is the only site on the West Coast.   Called HIFU (High Intensity Focused Ultrasound), the technique delivers sound waves aimed at the prostate tissue, which rapidly increases tissue temperature, destroying the cancerous lesions.

Three months after Dwight had the HIFU outpatient procedure at UCLA his PSA levels were undetectable. His UCLA urologists, Dr. Leonard Marks and Dr. Allan Pantuck, are pleased with these early results.  Although his doctors note that Dwight's experience may not be typical and side effects may vary amongst patients. 

To qualify for the clinical trial, participants must have recurrent prostate cancer after treatment with external beam radiation therapy.  Initial screening visits will involve physical exams, blood tests and an ultrasound of the prostate.  Qualifying participants will receive the outpatient HIFU procedure under anesthesia and follow-up for a year after treatment. All study-related costs, including the HIFU treatment, will be covered by the research study.

The study is sponsored by Focus Surgery, Inc., manufacturer of the The Sonablate® 500 system,  which is the HIFU technology used in the study.   Several thousand HIFU procedures have been performed in other countries, but the treatment is currently considered investigational in the United States.  The UCLA study is part of an FDA-approved clinical trial.

For more information about the study, please call Malu Macairan, research coordinator, at 310-794-3566.

Learn More

Click below to learn more about the

  • UCLA Prostate Cancer Program
  • or contact us at (310) 794-3566

Learn more about Dr. Leonard Marks and Dr. Allan Pantuck.

Visit our Health Encyclopedia for more information on prostate cancer.

Click here for more patient stories.

Visit us on FACEBOOK to share your story.

stay connected   Twitter Facebook You Tube RSS Mobile